Case Study

Usefulness of Pirfenidone in Covid Lung: A Case Series

Abdul Basit Ibne Momen
Bangladesh Medical College, Bangladesh
* Corresponding author
Farhana Khan
Ad-Din Women’s Medical College, Bangladesh
Sadia Saber
Bangladesh Medical College, Bangladesh
Amrin Sultana
Bangladesh Medical College, Bangladesh
Rafa Faaria Alam
Bangladesh Medical College, Bangladesh
Sheikh Golam Raihan
Bangladesh Medical College, Bangladesh
Mohammad Monower Hossain
Bangladesh Medical College, Bangladesh
Md Tarek Alam
Bangladesh Medical College, Bangladesh
DOI icon 10.24018/ejmed.2021.3.1.670

Read Counter
14619

Downloads
12958

Citations

Share

Article Sidebar

Submitted 2021-01-09
Published 2021-01-19

Read counter = 14619 times

Table of Contents

Article Main Content

The year 2020 has been plagued by the COVID‑19 pandemic that has resulted in an additional 1,800,000 deaths worldwide. Many patients who recover from Covid-19 later present with shortness of breath and fibrosis of the lungs, while some take a long time to recover from the initial infection. A drug such as pirfenidone, which has been used for the treatment of idiopathic pulmonary fibrosis, could offer additional benefits by reverting pulmonary fibrotic damage. Here we describe a case series of five patients where addition of this drug showed marked improvement in symptoms and radiological findings. Apart from the efforts regarding understanding the pathophysiology of this new disease, we must also evaluate the proportion of patients that develop chronic lung disease due to fibrosis following COVID-19 recovery. Certainly, more attention should be given to new studies to determine the actual benefit of pirfenidone in patients with pulmonary fibrosis as a result of Covid-19 infection.

Keywords: COVID-19, Pirfenidone, Pulmonary Fibrosis

References

  1. Li YC, Bai WZ, Hashikawa T. The neuroinvasive potential of SARS‐CoV2 may play a role in the respiratory failure of COVID‐19 patients. Journal of medical virology. 2020 Jun;92(6):552-5. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 382:727–733.
    DOI  |   Google Scholar
  2. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 (2020) Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 382:1708–1720
    DOI  |   Google Scholar
  3. King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. The Lancet Respiratory Medicine. 2017 Jan 1;5(1):72-84.
    DOI  |   Google Scholar
  4. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, Axmann J, Kirchgaessler KU, Samara K, Gilberg F, Cottin V. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet Respiratory Medicine. 2020 Feb 1;8(2):147-57.
    DOI  |   Google Scholar
  5. Yang Y, Ye Y, Lin X, Wu K, Yu M. Inhibition of pirfenidone on TGF-beta2 induced proliferation, migration and epithlial-mesenchymal transition of human lens epithelial cells line SRA01/04. PloS one. 2013 Feb 21;8(2): e56837.
    DOI  |   Google Scholar
  6. Lancaster LH, de Andrade JA, Zibrak JD, Padilla ML, Albera C, Nathan SD, Wijsenbeek MS, Stauffer JL, Kirchgaessler KU, Costabel U. Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis. European respiratory review. 2017 Dec 31;26(146).
    DOI  |   Google Scholar
  7. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. The Lancet Respiratory Medicine. 2020 May 15.
    DOI  |   Google Scholar
  8. Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello A. The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. European Journal of Clinical Pharmacology. 2020 Nov;76(11):1615-8.
    DOI  |   Google Scholar
  9. Li Y, Li H, Liu S, Pan P, Su X, Tan H, Wu D, Zhang L, Song C, Dai M, Li Q. Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation. Molecular immunology. 2018 Jul 1; 99:134-44.
    DOI  |   Google Scholar
  10. Saha A, Vaidya PJ, Chavhan VB, Achlerkar A, Leuppi JD, Chhajed PN. Combined pirfenidone, azithromycin and prednisolone in post-H1N1 ARDS pulmonary fibrosis. Sarcoidosis, Vasculitis, and Diffuse Lung Diseases. 2018;35(1):85.
     Google Scholar


Most read articles by the same author(s)